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Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly 36 
developed to help restore the massive health and economic disruption caused by the coronavirus 37 
disease 2019 (COVID-19) pandemic. By single cell sorting 4,277 SARS-CoV-2 spike protein 38 
specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified. 39 
The most potent neutralizing antibodies recognized the spike protein receptor binding domain, 40 
followed in potency by antibodies that recognize the S1 domain, the spike protein trimer and the S2 41 
subunit. Only 1.4% of them neutralized the authentic virus with a potency of 1-10 ng/mL. The most 42 
potent monoclonal antibody, engineered to reduce the risk of antibody dependent enhancement 43 
and prolong half-life, neutralized the authentic wild type virus and emerging variants containing 44 
D614G, E484K and N501Y substitutions. Prophylactic and therapeutic efficacy in the hamster 45 











The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, with 48 
more than 100 million cases, over 2 million deaths, an estimated cost of 16 trillion US dollars to the 49 
USA economy (Cutler and Summers, 2020) and 45 million people filing unemployment in the 50 
United States alone, is unprecedented (Aratani, 2020).  51 
Vaccines and drugs against SARS-CoV-2 have recently received emergency use authorization 52 
(EUA) by the Food and Drug Administration (FDA) for prevention and treatment of coronavirus 53 
disease 2019 (COVID-19) (FDA, 2021, FDA, 2020).  54 
In spite of this, it is predictable that waves of infection will continue to spread globally and it is likely 55 
to be followed by additional waves over the next few years. This is supported by the emergence of 56 
new SARS-CoV-2 variants in the United Kingdom, South Africa, Brazil and Japan (CDC, 2021).  57 
It is therefore imperative to quickly develop, in parallel to vaccines, therapeutic tools against SARS-58 
CoV-2 and its variants. Among the many therapeutic options available, human monoclonal 59 
antibodies (mAbs) can be developed in the shortest time frame. In fact, the extensive clinical 60 
experience with the safety of more than 50 commercially available mAbs approved to treat cancer, 61 
inflammatory and autoimmune disorders, provides high confidence of their safety (Wellcome, 62 
2020). These advantages, combined with the urgency of the SARS-CoV-2 pandemic, support and 63 
justify an accelerated regulatory pathway. In addition, the long industrial experience in developing 64 
and manufacturing mAbs decreases risks usually associated with technical development of 65 
investigational products. Finally, the incredible technical progress in this field allows shortening of 66 
conventional timelines and enables a path from discovery to proof of concept trials within 5-6 67 
months (Kelley, 2020). A key example is the Ebola case, where mAbs were developed faster than 68 
vaccines or other drugs (Kupferschmidt, 2019) becoming the first therapeutic intervention 69 
recommended by the World Health Organization (WHO) and approved by the Food and Drug 70 
Administration (FDA) (Mullard, 2020).  71 
During the first months of this pandemic many groups have been active in isolating and 72 
characterizing human monoclonal antibodies from COVID-19 convalescent patients or from 73 










prevention and cure of SARS-CoV-2 infection (Shi et al., 2020, Hansen et al., 2020, Hsieh et al., 75 
2020, Pinto et al., 2020, Zost et al., 2020a, Zost et al., 2020b, Rogers et al., 2020, Alsoussi et al., 76 
2020). Few of them are already in phase III clinical trials and reported promising preliminary 77 
results. Two of them received the Emergency Use Authorization from the FDA (Lilly, 2020, 78 
Regeneron, 2020).   79 
All these antibodies neutralize SARS-CoV-2 infection by binding to the spike glycoprotein (S-80 
protein), a trimeric class I viral fusion protein which mediates virus entry into host cells by engaging 81 
with the human angiotensin converting enzyme 2 (hACE2) and cellular heparan sulfate as 82 
receptors (Clausen et al., 2020). The S-protein exists in a metastable pre-fusion conformation and 83 
in a stable post-fusion form (Wang et al., 2020, Walls et al., 2020, Schäfer et al., 2020). Each S-84 
protein monomer is composed of two distinct regions, the S1 and S2 subunits. The S1 subunit 85 
contains the receptor binding domain (RBD) which is responsible for the interaction with hACE2 86 
and heparan sulfate on host cell membranes triggering the destabilization of the prefusion state of 87 
the S-protein and consequent transition into the post-fusion conformation. This event results in the 88 
entry of the virus particle into the host cell and the onset of infection (Wrapp et al., 2020, Walls et 89 
al., 2020, Tay et al., 2020, Zou et al., 2020). 90 
As for other mAbs in the field of infectious diseases (Hooft van Huijsduijnen et al., 2020, Sparrow et 91 
al., 2017), the dose of mAbs so far used in clinical trials against SARS-CoV-2 is high, ranging from 92 
500 to 8,000 mgs (NCT04411628; NCT04427501; NCT04441918; NCT04425629; NCT04426695; 93 
NCT04452318). The high dose poses two important limits to the application of mAbs in the 94 
infectious diseases field. Firstly, the high dosage has cost-associated implications and it only 95 
allows for intravenous delivery making this therapeutic intervention extremely costly and therefore 96 
available almost exclusively in high-income countries. Indeed, the high price of this intervention has 97 
been a barrier to the global access of mAbs and their use to other fields such as infectious 98 
diseases. A solution would be the development of extremely potent mAbs that can be used at lower 99 
dosages leading to cost reductions and that can be delivered via intramuscular or subcutaneous 100 










recently shown its therapeutic effect in premature infants after only one intramuscular injection of 102 
50 mg (Griffin et al., 2020).  103 
The second limit of mAbs in the field of infectious diseases is the risk of antibody dependent 104 
enhancement (ADE) of disease which is usually mediated by the binding of the fragment 105 
crystallizable region (Fc) portion of the antibody to Fc gamma receptors (FcγRs) expressed by 106 
immune cells (Lee et al., 2020). ADE has been clearly demonstrated in the case of SARS-CoV, 107 
RSV and dengue viruses and the theoretical risk has been raised in the case of SARS-CoV-2 (Lee 108 
et al., 2020, Katzelnick et al., 2017, Arvin et al., 2020).  109 
In this work we pushed the limits of mAb application to fight infectious diseases by selecting 110 
extremely potent antibodies with the aim of using them at low dosage, to make them affordable and 111 
conveniently delivered by intramuscular injection. In addition, we mitigated the risk of ADE by 112 
engineering their Fc region. Despite complete lack of Fc-receptor binding and Fc-mediated cellular 113 
activities, engineered mAbs were able to prevent and treat SARS-CoV-2 infection in golden Syrian 114 
hamster at a concentration of 0.25 and 4 mg/kg respectively. These antibodies have the potential 115 











Isolation and characterization of S-protein specific antibodies from SARS-CoV-2 convalescent 118 
patients 119 
To retrieve mAbs specific for SARS-CoV-2 S-protein, peripheral blood mononuclear cells (PBMCs) 120 
from fourteen COVID-19 convalescent patients enrolled in this study were collected and stained 121 
with fluorescently labelled S-protein trimer to identify antigen specific memory B cells (MBCs). 122 
Figure 1 summarizes the overall experimental strategy. The gating strategy described in Figure 123 
S1A was used to single cell sort, into 384-well plates, IgG+ and IgA+ MBCs binding to the SARS-124 
CoV-2 S-protein trimer in its prefusion conformation. The sorting strategy aimed to specifically 125 
identify class-switched MBCs (CD19+CD27+IgD-IgM-) to identify only memory B lymphocytes that 126 
underwent maturation processes. A total of 4,277 S-protein-binding MBCs were successfully 127 
retrieved with frequencies ranging from 0.17% to 1.41% (Table S1). Following the sorting 128 
procedure, S-protein+ MBCs were incubated over a layer of 3T3-CD40L feeder cells in the 129 
presence of IL-2 and IL-21 stimuli for two weeks to allow natural production of immunoglobulins 130 
(Huang et al., 2013). Subsequently, MBC supernatants containing IgG or IgA were tested for their 131 
ability to bind either the SARS-CoV-2 S-protein trimer in its prefusion conformation or the S-protein 132 
S1 + S2 subunits (Figure 2A and Figure S2B) by enzyme linked immunosorbent assay (ELISA). A 133 
panel of 1,731 mAbs specific for the SARS-CoV-2 S-protein were identified showing a broad range 134 
of signal intensities (Figure 2A; Table S1).  135 
 136 
Identification of S-protein specific mAbs able to neutralize SARS-CoV-2   137 
The 1,731 supernatants containing S-protein specific mAbs, were screened in vitro for their ability 138 
to block the binding of the streptavidin-labelled S-protein to Vero E6 cell receptors and for their 139 
ability to neutralize authentic SARS-CoV-2 virus by in vitro microneutralization assay. In the 140 
neutralization of binding (NoB) assay, 339 of the 1,731 tested (19.6%) S-protein specific mAbs 141 
were able to neutralize the antigen/receptor binding showing a broad array of neutralization 142 










As for the authentic virus neutralization assay, supernatants containing naturally produced IgG or 144 
IgA were tested for their ability to protect the layer of Vero E6 cells from the cytopathic effect 145 
triggered by SARS-CoV-2 infection. To increase the throughput of our approach, supernatants 146 
were tested at a single point dilution and to increase the sensitivity of our first screening a viral titer 147 
of 25 TCID50 was used. For this screening mAbs were classified as neutralizing, partially 148 
neutralizing and non-neutralizing based on their complete, partial or absent ability to prevent the 149 
infection of Vero E6 cells respectively. Out of 1,731 mAbs tested in this study, a panel of 453 150 
(26.2%) mAbs neutralized the authentic virus and prevented infection of Vero E6 cells (Table S1). 151 
The percentage of partially neutralizing mAbs and neutralizing mAbs (nAbs) identified in each 152 
donor was extremely variable ranging from 2.6 – 29.7% and 2.8 – 26.4% respectively (Figure 2B 153 
and Table S2). The majority of nAbs were able to specifically recognize the S-protein S1 domain 154 
(57.5%; N=244) while 7.3% (N=53) of nAbs were specific for the S2 domain and 35.2% (N=156) 155 
did not recognize single domains but only the S-protein in its trimeric conformation (Figure S2A; 156 
Table S3). From the panel of 453 nAbs, we recovered the heavy and light chain variable regions of 157 
220 nAbs which were expressed as full length IgG1 using the transcriptionally active PCR (TAP) 158 
approach to characterize their neutralization potency against the live virus at 100 TCID50. The vast 159 
majority of nAbs identified (65.9%; N=145) had a low neutralizing potency and required more than 160 
500 ng/mL to achieve 100% inhibitory concentration (IC100). A smaller fraction of the antibodies had 161 
an intermediate neutralizing potency (23.6%; N=52) requiring between 100 and 500 ng/mL to 162 
achieve the IC100, while 9.1% (N=20) required between 10 and 100 ng/mL. Finally, only 1.4% (N=3) 163 
of the expressed nAbs were classified as extremely potent nAbs, showing an IC100 lower than 10 164 
ng/mL (Figure 2C and Figure S2B; Table S4). 165 
 166 
SARS-CoV-2 neutralizing antibodies can be classified into four groups 167 
Based on the first round of screening, 14 nAbs were selected for further characterization. All nAbs 168 
were able to bind the SARS-CoV-2 S-protein in its trimeric conformation (Figure 3A). The mAbs 169 
named J08, I14, F05, G12, C14, B07, I21, J13 and D14 were also able to specifically bind the S1 170 










domains but only the S-protein in its trimeric state, while the nAb L19 bound only the S2 subunit 172 
(Figure 3B - C). Among the group of S1 specific nAbs only J08, I14, F05, G12, C14 and B07 were 173 
able to bind the S1-RBD and to strongly inhibit the interaction between the S-protein and Vero E6 174 
receptors showing a half maximal effective concentration (EC50) at the NoB assay of 78.6, 15.6 and 175 
68.5 ng/mL for J08-MUT, I14-MUT and F05-MUT respectively (Figure S3A - B). On the other hand, 176 
I21, J13 and D14, despite showing S1 binding specificity, did not show any binding to the RBD and 177 
NoB activity (Figure S3A). Based on this description four different groups of nAbs against SARS-178 
CoV-2 were identified. The first group (Group I) is composed of S1-RBD specific nAbs (J08, I14, 179 
F05, G12, C14 and B07) which showed neutralization potency against the authentic wild type (WT), 180 
the D614G variant and the emerging variant recently isolated in the UK B.1.1.7. S1-RBD specific 181 
nAbs showed a neutralizing potency ranging from 3.9 to 157.5 ng/mL (Figure 3D - I; Table S5) and 182 
picomolar affinity to the S-protein with a KD ranging from 0.2 to 4.6 E-10M (Figure S4). In addition to 183 
the D616G and the B.1.1.7 variants, the S1-RBD specific nAb J08 showed also to neutralize 184 
SARS-CoV-2 variants containing the E484K mutation (Andreano et al., 2020). The second group 185 
(Group II) included S1-specific nAbs that did not bind the RBD (I21, J13 and D14). These 186 
antibodies also showed good neutralization potency ranging from 99.2 to 500.0 ng/mL (Figure 3D - 187 
I; Table S5) but inferior to that of S1-RBD directed nAbs. One antibody from this group was not 188 
able to neutralize the B.1.1.7 variant (I21). The third group (Group III) is composed by antibodies 189 
able to bind the S-protein only in its whole trimeric conformation (H20, I15, F10 and F20). 190 
Antibodies belonging to this group showed lower affinity to the S-protein trimer (KD 64.0 E-10M – 191 
757.0 E-10M) compared to Group I nAbs and medium neutralization potencies ranging from 155.0 to 192 
492.2 ng/mL against the authentic WT and D614G (Figure 3D - I; Table S5; Figure S4). On the 193 
other hand, only one S-protein specific nAb (D21) showed moderate neutralization activity against 194 
the B.1.1.7 with an IC100 of 500.0 ng/mL. Three S-protein specific nAbs (I15, F10 and F20) did not 195 
show any functional activity against this latter variant (Figure 3D - I; Table S5). The fourth and final 196 
group (Group IV) is composed of antibodies that exclusively recognized the S2 domain. Different 197 
antibodies with similar properties were identified for the Group IV but only the nAb L19 is shown. 198 










WT, 12.5 µg/mL against the D614G, and 9.9 µg/mL against the B.1.1.7 variant (Figure 3D - I; Table 200 
S5).  201 
All the antibodies described above were also tested for their ability to cross-neutralize other human 202 
coronavirus strains. nAbs were tested against lentiviral pseudotypes expressing the SARS-CoV-2, 203 
SARS-CoV-2 D614G, SARS-CoV and Middle East Respiratory Syndrome (MERS-CoV) spike 204 
protein on their viral membrane surface. Neutralization activity was shown against SARS-CoV-2 205 
and D614G pseudotypes and therefore confirming previous data. None of the antibodies herein 206 
reported were able to cross-neutralize other coronavirus species (Figure S5).  207 
 208 
Different pathogen vulnerability regions identified on the S-protein 209 
The fourteen selected nAbs were further characterized by a competition assay that allowed 210 
speculation on the S-protein regions recognized by these antibodies. Briefly, beads were coated 211 
with SARS-CoV-2 trimeric S-protein and incubated with a primary unlabeled antibody in order to 212 
saturate the binding site on the antigen surface. Following the first incubation step a secondary 213 
Alexa-647 labeled antibody was incubated with the antigen/unlabeled-mAb complex. If the 214 
secondary labeled-antibody did not recognize the same epitope as the primary unlabeled-mAb a 215 
fluorescent signal would be detected when tested by flow cytometry. Through this assay, we 216 
observed that all Group I nAbs competed amongst themselves for binding to the S-protein RBD, 217 
indicating that these antibodies possibly clash against each other and recognize a similar epitope 218 
region. All Group II nAbs, showed a different competition profiles and competed with Group II and 219 
Group III nAbs. These results confirmed that Group III antibodies can recognize various regions on 220 
the S-protein surface as they compete with themselves as well as with antibodies belonging to 221 
Group II. Interestingly, nAbs belonging to Group II also competed with the B07 RBD-directed 222 
antibody and thereby suggesting that this latter nAb may have a different binding orientation 223 
compared to other nAbs included in the Group I. Finally, the Group IV nAb L19 did not compete 224 
with any of the other groups identified in this study suggesting that this class of nAbs recognize a 225 











Genetic characterization of SARS-CoV-2 nAbs 228 
The genes encoding the heavy and light chains of the 14 selected nAbs, were sequenced and their 229 
IGHV and IGKV genes compared with publicly available SARS-CoV-2 neutralizing antibody 230 
sequences (Figure 5A – B). Four nAbs used one of the most predominant heavy chain V genes for 231 
SARS-CoV-2 nAbs (IGHV1-69), while three nAbs used one of the least representative heavy chain 232 
V genes (IGHV1-24). Other two nAbs, employed the most common germline observed for SARS-233 
CoV-2 nAbs which is  IGHV3-53 (Figure 5A) (Yuan et al., 2020). Interestingly, while IGHV1-69 and 234 
IGHV1-24 accommodate IGHJ diversity, nAbs belonging to the IGHV3-53 gene family only showed 235 
recombination with the IGHJ6 gene (Table S6). The heavy chain V genes somatic hypermutation 236 
level and complementary determining region 3 (H-CDR3) length were also evaluated. Our selected 237 
nAbs displayed a low level of somatic mutations when compared to the inferred germlines with 238 
sequence identities ranging from 95.6 to 99.3% (Figure 5C left panel; Table S6) confirming what 239 
was observed in previous publications (Pinto et al., 2020, Zost et al., 2020b, Rogers et al., 2020, 240 
Griffin et al., 2020). The H-CDR3 length spanned from 7 to 21 amino acids (aa) with the majority of 241 
the antibodies (N=6; 42.0%) having a length of 14 to 16 aa that is slightly bigger than previously 242 
observed (Figure 5C right panel; Table S6). All of our nAbs used the κ-chain and the majority of 243 
them used the common genes IGKV1-9 and IGKV3-11 (N=6; 42.0%) (Figure 5B; Table S6). The 244 
level of IGKV somatic hypermutation was extremely low for light chains showing a percentage of 245 
sequence identities ranging from 94.3 to 98.9% (Figure 5D left panel; Table S6). The light chain 246 
CDR3 (L-CDR3) length were ranging from 5 to 10 aa which is in line with what was previously 247 
observed for SARS-CoV-2 nAbs (Figure 5D right panel; Table S6). When paired heavy and light 248 
chain gene analysis was performed, IGHV1-69 derived nAbs were found to rearrange exclusively 249 
with IGKV3 gene family while IGHV1-24 derived nAbs accommodate light chain diversity (Table 250 
S6). Of note, some of our candidates showed unique heavy and light chain pairing when compared 251 
to the public SARS-CoV-2 nAb repertoire. Particularly, five different heavy and light chain 252 
rearrangements not previously described for nAbs against SARS-CoV-2 were identified. These 253 
included the IGHV1-24;IGKV1-9, IGHV1-24;IGKV3-15, IGHV1-46;IGKV1-16, IGHV3-30;IGKV1-9, 254 










Fc-engineering of candidate nAbs to abrogate Fc receptor binding and extend half-life  256 
Antibody-dependent enhancement (ADE) of disease, is a potential clinical risk following 257 
coronavirus infection (Lee et al., 2020). Therefore, to optimize the suitability for clinical 258 
development and reduce the risk of ADE, five different point mutations were introduced in the 259 
constant region (Fc) of the three most potent nAbs (J08, I14 and F05) which were renamed J08-260 
MUT, I14-MUT and F05-MUT. The first two point mutations (M428L/N434S) were introduced to 261 
enhance antibody half-life and to increase tissue distribution and persistence (Zalevsky et al., 262 
2010, Gaudinski et al., 2018, Pegu et al., 2017). The remaining three point mutations 263 
(L234A/L235A/ P329G) were introduced to reduce antibody dependent functions such as binding to 264 
FcγRs and cell-based activities (Schlothauer et al., 2016).  265 
To confirm the lack of FcγR binding as well as the extended half-life, a beads-based Luminex 266 
assay was performed. Briefly the beads were coated with SARS-CoV-2 S-protein RBD. Antibodies 267 
were tested at eight-point dilutions and the binding was detected with FcγR2A and neonatal Fc 268 
receptor (FcRn) at pH6.2 and 7.4. The FcγR2A was selected as it is predominantly expressed on 269 
the surface of phagocytic cells (such as monocytes, macrophages and neutrophils) and is 270 
associated with phagocytosis of immune complexes and antibody-opsonized targets (Ackerman et 271 
al., 2013). On the other hand, FcRn, which is highly expressed on endothelial cells and circulating 272 
monocytes, was selected as it is responsible for the recycling and serum half-life of IgG in the 273 
circulation (Mackness et al., 2019). This latter receptor was shown to possess a tighter binding at 274 
lower pH (e.g. pH 6.2) compared to a physiological pH (e.g. pH 7.4) (Booth et al., 2018). Results 275 
shown in Figure S6 demonstrate that binding to the FcγR2A was completely abrogated for the 276 
mutated version of candidate nAbs (J08-MUT, I14-MUT and F05-MUT) compared to their 277 
respective wild type (WT) versions (J08, I14 and F05) and controls (CR3022 and unrelated protein) 278 
(Figure S6A). Furthermore, Fc-engineered antibodies showed increased binding activity to the 279 
FcRn at both pH 6.2 and 7.4 compared to their WT counterpart (Figure S6B – C). Finally, to 280 
evaluate the lack of Fc-mediated cellular activities by our three candidate nAbs, the antibody-281 
dependent neutrophil phagocytosis (ADNP) and antibody-dependent NK cell activation (ADNK) 282 










2020). For the ADNP assay, primary human neutrophils were used to detect antibody binding to 284 
SARS-CoV-2 S-protein RBD coated beads, while ADNK activity was evaluated by using primary 285 
human NK cells and detecting the release of the proinflammatory cytokine interferon gamma (IFN-286 
γ). Complete abrogation of both ADNP and ADNK was observed for all three Fc-engineered 287 
candidate nAbs compared to their WT versions and control antibody (CR3022), thus confirming the 288 
lack of Fc-mediated cellular activities (Figure S6D – E). 289 
 290 
Potency and autoreactivity evaluation of Fc-engineered candidates  291 
The three engineered antibodies were tested to confirm their binding specificity and neutralization 292 
potency against both the WT, the widespread SARS-CoV-2 D614G mutant and the emerging 293 
variant B.1.1.7 (Korber et al., 2020, CDC, 2021) to evaluate their cross-neutralization ability. The 294 
three engineered nAbs maintained their S1-domain binding specificity and extremely high 295 
neutralization potency with J08-MUT and F05-MUT being able to neutralize both the WT and the 296 
D614G variant with an IC100 lower than 10 ng/mL (both at 3.9 ng/mL for the WT and the D614G 297 
strains) (Figure S6F – K; Table S5). The antibody J08-MUT also showed extreme neutralization 298 
potency against emerging variants as it was able to neutralize the B.1.1.7 with an identical IC100 299 
compared to the WT virus (Figure S6K; Table S5) and has also showed to neutralize variants that 300 
include the E484K mutation (Andreano et al., 2020). 301 
Since it has been reported that SARS-CoV-2 elicited antibodies that can cross-react with human 302 
tissues, cytokines, phospholipids and phospholipid-binding proteins (Zuo et al., 2020, Bastard et 303 
al., 2020, Kreer et al., 2020), the three candidate mAbs in both their WT and MUT versions were 304 
tested through an indirect immunofluorescent assay against human epithelial type 2 (HEp-2) cells 305 
which expose clinically relevant proteins to detect autoantibody activities (Figure S7A). As reported 306 
in Figure S7B, the positive control presents a different range of detectable signals based on the 307 
initial dilution steps (from bright-green at 1:1 to very dim-green at 1:100). Among all samples 308 
tested, only F05 showed moderate level of autoreactivity to human cells while no signal could be 309 











Structural analyses of candidate nAbs 312 
Single particle negative stain electron microscopy (nsEM) was used to visualize a stabilized SARS-313 
2-CoV-6P-Mut7 spike protein in complex with three separate Fabs: J08, I14 and F05. This 314 
recombinant, soluble spike protein primarily exhibits 3 RBD’s “down” but can switch to RBD “up” 315 
conformation with antibody bound. Inspection of the 2D class averages revealed a mixed 316 
stoichiometry of unbound spike protein, 1 Fab bound, and 2 Fab bound classes, which allowed for 317 
3D refinements of each (Figure 6A). The three different Fabs bind to the RBD in the “up” 318 
conformation, although at different angles and rotations, likely due to the flexibility of the RBD. 319 
Model docking of PDB 7BYR (one RBD “up” bound to antibody) shows that the fabs overlap with 320 
the receptor binding motif (RBM), and therefore are positioned to sterically block receptor hACE2 321 
engagement (Figure 6B). To determine the epitope, heavy chain (HC) and light chain (LC) 322 
sequences of Fabs J08, I14, and F05 were used to create synthetic models for docking into the 323 
nsEM maps. Based on the docking, we predicted that a loop containing residues 477 to 489 324 
(STPCNGVEGFNCY) appeared to be involved in the binding specifically with residue F486 325 
extending into a cavity that is in the middle of the HC and LC of each antibody.  326 
 327 
J08-MUT prevents SARS-CoV-2 infection in the golden Syrian hamster  328 
The golden Syrian hamster model has been widely used to assess monoclonal antibody 329 
prophylactic and therapeutic activities against SARS-CoV-2 infection. This model has shown to 330 
manifest severe forms of SARS-CoV-2 infection mimicking more closely the clinical disease 331 
observed in humans (Baum et al., 2020, Imai et al., 2020, Rogers et al., 2020, Sia et al., 2020). We 332 
designed a prophylactic study in golden Syrian hamster to evaluate the efficacy of J08-MUT in 333 
preventing SARS-CoV-2 infection. For this study 30 hamsters were divided into 5 arms (six animals 334 
each) which received, J08-MUT at 4, 1 and 0.25 mg/kg via intraperitoneal injection. Placebo and 335 
IgG1 isotype control groups were included in the study which received a saline solution and an 336 
anti-influenza antibody at the concentration of 4 mg/kg respectively. The J08-MUT at 4 mg/kg 337 
group and the 1 and 0.25 mg/kg groups were tested in two independent experiments. The IgG1 338 
isotype control group was tested in parallel with the J08-MUT 4 mg/kg group while the placebo is 339 










(5 x 105 PFU) via intranasal distillation twenty four hours post-administration of the antibody. Three 341 
hamsters per group were sacrificed at three days post-infection while the remaining animals were 342 
culled at day 8 (Figure 7A). Body weight change was daily evaluated and considered as a proxy for 343 
disease severity. Animals in the control group and those that received the IgG1 isotype antibody 344 
lost more than 5% of their original body weight from day 1 to day 6 and then stabilized. These data 345 
are in line with previously published data of SARS-CoV-2 infection in a golden Syrian hamster 346 
model (Kreye et al., 2020, Liu et al., 2020). In marked contrast, in the prophylactic study, all 347 
animals that received J08-MUT were significantly protected from weight loss. Protection was 348 
present at all J08-MUT concentrations and was dose dependent (Figure 7B). When J08-MUT was 349 
administered at 4 mg/kg we observed protection from SARS-CoV-2 infection and only a minimal 350 
weight loss (average -1.8% of body weight) was noticed one day post viral challenge. A higher 351 
body weight loss was observed 1 day post infection in hamsters that received J08-MUT at 1 mg/kg 352 
(from -1.8% to -3.3%) and 0.25 mg/kg (from -1.8% to -4.7%). In the J08-MUT 4 mg/kg group all 353 
animals quickly recovered and reached their initial weight by day 3. From day 4 on all hamsters 354 
gained weight increasing up to 5% from their initial body weight. Hamsters that received the 1 and 355 
0.25 mg/kg dosages completely recovered their initial body weight at day 6 and 8 respectively. 356 
Hamsters in the control groups did not recover their initial body weight and at day 8 still showed 357 
around 5% of weight loss (Figure 7B). The prophylactic activity of J08-MUT was also reflected in 358 
the complete absence of viral titer in the lung tissue at three days post-infection in all hamsters that 359 
received J08-MUT at 4 and 1 mg/kg and also in two out of three hamsters that received J08-MUT 360 
at 0.25 mg/kg. On the other hand, hamsters that received the IgG1 isotype control or in the placebo 361 
group showed a significantly higher viral titer (Figure 7D).  362 
Finally, we performed an ELISA assay to detect the presence of human IgG in hamster sera. All 363 
samples that received J08-MUT or the IgG1 isotype control showed detectable human IgGs in the 364 
sera in a dose-dependent fashion, while no human IgGs were detected in the placebo group 365 
(Figure 7E – F). Human IgGs were detected at three and up to seven days post infection (Figure 7E 366 











J08-MUT therapy of SARS-CoV-2 infection in the golden Syrian hamster  369 
For the therapeutic study, 3 groups of 6 animals each were used to evaluate the ability of J08-MUT 370 
to treat SARS-CoV-2 infection in the golden Syrian hamster model. One group received J08-MUT 371 
via intraperitoneal injection at 4 mg/kg and the other two groups received placebo and 4mg/kg IgG1 372 
isotype control respectively. The experiment  was performed  in parallel with the initial prophylactic, 373 
study where J08-MUT was administered at 4 mg/kg, and the two control groups. Animals were 374 
challenged with 100 µL of SARS-CoV-2 solution (5 x 105 PFU) via intranasal distillation twenty four 375 
hours prior to the administration of the antibody. Three hamsters per group were sacrificed at three 376 
days post-infection while the remaining animals were culled at day 12 (Figure 7A). Despite J08-377 
MUT and control groups showed a similar trend in weight loss in the first four days post-infection, 378 
the treatment group showed a significantly quicker weight recovery (Figure 7C). At day 12, only 379 
hamsters that received J08-MUT recovered the initial body weight (Figure 7C). When we analyzed 380 
the viral titer in lung tissues we observed complete absence of the virus at day 3 in all the hamsters 381 
treated with J08-MUT at 4 mg/kg while animals that received the IgG1 isotype control or in the 382 
placebo group showed a significantly higher viral titer (Figure 7G). To evaluate the presence of 383 
human antibodies in hamster sera, we performed an ELISA assay. All samples that received J08-384 
MUT or the IgG1 isotype control showed detectable human IgGs in the sera in a dose-dependent 385 
fashion, while no human IgGs were detected in the placebo group (Figure 7H – I). Human IgGs 386 
were detected at three and up to 11 days post infection (Figure 7H – I).  387 











This work describes a systematic screening of memory B cells from SARS-CoV-2 convalescent 390 
patients to identify extremely potent mAbs against SARS-CoV-2 and their engineering to extend 391 
half-life and eliminate the potential risk of ADE. The best antibody neutralized the authentic wild 392 
type virus and emerging variants at pico molar concentration in vitro and showed prophylactic and 393 
therapeutic efficacy in a SARS-CoV-2 hamsters model of infection when used at 0.25 and 4 mg/kg 394 
respectively. The antibody described is a promising candidate for the development of a broadly 395 
affordable tool for prevention and therapy of COVID-19.  396 
In the search for potent antibodies, we found that approximately 10% of the total B cells against the 397 
S-protein isolated produce neutralizing antibodies and these can be divided into 4 different groups 398 
recognizing the S1-RBD, S1-domain, S2-domain and the S-protein trimer. Most potently 399 
neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by 400 
antibodies recognizing the S1 domain, the trimeric structure and the S2 subunit. From these data 401 
we can conclude that in COVID-19 convalescent patients most of the observed neutralization titers 402 
are likely mediated by antibodies with medium-high neutralizing potency. Indeed, the extremely 403 
potent antibodies and the antibodies against the S2 subunit are unlikely to contribute to the overall 404 
neutralizing titers because they are respectively too rare and too poor neutralizers to be able to 405 
make a difference. We and others found that the antibody repertoire of convalescent patients is 406 
mostly germline-like. This may be a consequence of the loss of Bcl-6-expressing follicular helper T 407 
cells and the loss of germinal centers in COVID-19 patients which may limit and constrain the B cell 408 
affinity maturation (Kaneko et al., 2020). It will be therefore important to perform similar studies 409 
following vaccination as it is likely that the repertoire of neutralizing antibodies induced by 410 
vaccination may be different from the one described here.  411 
Out of the 453 neutralizing antibodies that were tested and characterized, one antibody (J08) 412 
showed extremely high neutralization potency against both the wild type SARS-CoV-2 virus 413 
isolated in Wuhan and emerging variants containing the D614G, E484K and N501Y variants. 414 
During the last few months several groups reported the identification, three-dimensional structure 415 










these studies, with few exceptions, reported antibodies which require from 20 to several hundred 417 
ng/mL to neutralize 50% of the virus in vitro. While these antibodies are potentially good for 418 
therapy, they will require a high dosage which is associated with elevated cost of goods, low 419 
production capacity and delivery by intravenous infusion.  420 
The extremely potent mAb described in our study is likely to allow to use lower quantities of 421 
antibodies to reach prophylactic and therapeutic efficacy and as a consequence decrease the cost 422 
of goods and enable sustainable development and manufacturability. This solution may increase 423 
the number of doses produced annually and therefore increase antibodies availability in high 424 
income countries as well as low-and middle-income countries (LMICs). Therefore our antibodies 425 
have the potential to meet the expectations of the call to action to expand access to monoclonal 426 
antibody-based products, recently published by the Wellcome Trust, and supported by the WHO 427 
and the Coalition for Epidemic Preparedness Innovations (CEPI) (Wellcome, 2020). 428 
A potential issue associated with the use of human monoclonal antibodies against viral pathogens 429 
is the potential selection of escape mutants. This is usually addressed by using a combination of 430 
antibodies directed against non-overlapping epitopes. While this is an ultimate clear solution, it 431 
increases the complexity of development, costs of production, drug availability and affordability. In 432 
our case we believe that selection of escape mutants upon treatment with a single monoclonal 433 
antibody may be quite difficult as the SARS-CoV-2 RNA-dependent polymerase possesses a 434 
proofreading machinery (Romano et al., 2020) and the epitope recognized by the antibodies herein 435 
described overlaps with the region necessary to bind the hACE2 receptor. In this regard, it took 436 
more than 70 days of continuous co-culture of the virus in presence of the antibodies before we 437 
were able to detect the first emergence of escape mutants of the wild-type SARS-CoV-2 (data not 438 
shown). 439 
Finally, a peculiar part of our approach consisted in depleting possible antibody Fc-mediated 440 
functions of the antibodies to avoid the risk of ADE. While there is no evidence of ADE in SARS-441 
CoV-2, and most vaccines and mAbs tested so far seem to be safe, it is too early to make definitive 442 
conclusions. In addition, two recently published reports suggested that we need to continue to 443 










characterized by an increased proinflammatory signature mediated by the Fcγ receptors triggered 445 
by afucosylated IgG1 antibodies (Chakraborty et al., 2020). The second report described that one 446 
antibody was associated with worse clinical outcomes when administered to hospitalized patients 447 
requiring high flow oxygen or mechanical ventilation (Lilly, 2020). Therefore, we believe it is 448 
important to develop and test antibodies where Fc-mediated functions have been eliminated in the 449 
clinical practice. Since the Fc portion contributes significantly to the in vivo potency of the 450 
antibodies (Schäfer et al., 2020), removing Fc-functions may be a problem for mAbs with low 451 
neutralization potency because they may no longer be effective when tested in clinical settings, as 452 
already described in other contexts (DiLillo et al., 2014). The extremely high potency shown by our 453 
antibodies allowed us to remove Fc-functions while maintaining in vivo potency at minimal dosage.  454 










Limitations of the study 456 
While we believe that our antibodies are extremely potent when compared to most of those 457 
described in literature, we acknowledge that in most cases direct comparison was not performed 458 
and we rely on published data. 459 
The second limitation of the study is that in vitro neutralization and in vivo protection in the SARS-460 
CoV-2 hamster model of infection cannot be fully predictive of the behavior of the same antibody in 461 
humans and therefore the real benefit of described antibodies can only be assessed in clinical 462 
studies.  463 
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FIGURE LEGENDS 522 
Figure 1. Workflow and timeline for SARS-CoV-2 neutralizing antibodies identification  523 
The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing 524 
antibodies (nAbs). Phase 1 consisted in the enrolment of Covid-19 patients (N=14) from which 525 
PBMCs were isolated. Memory B cells were single cell sorted (N=4,277) and after 2 weeks of 526 
incubation antibodies were screened for their binding specificity against the S-protein trimer and 527 
S1/S2 domains. Once S-protein specific monoclonal antibodies were identified (N=1,731) phase 2 528 
started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the 529 
authentic SARS-CoV-2 virus and 453 nAbs were identified. nAbs showing different binding profiles 530 
on the S-protein surface were selected for further functional characterization and to identify 531 
different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy 532 
and light chain sequences of selected mAbs (N=14) and the engineering of the Fc-portion of three 533 
most promising candidates. These latter were also selected for structural analyses that allowed the 534 
identification of the neutralizing epitopes on the S-protein. Finally, the most potent antibody was 535 
tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 536 
infection. 537 
 538 
Figure 2. Identification of SARS-CoV-2 S-protein specific neutralizing antibodies (nAbs)  539 
(A) The graph shows supernatants tested for binding to the SARS-CoV-2 S-protein stabilized in its 540 
prefusion conformation. Threshold of positivity has been set as two times the value of the blank 541 
(dotted line). Red dots represent mAbs which bind to the S-protein while pink dots represent mAbs 542 
which do not bind. (B) The bar graph shows the percentage of non-neutralizing (gray), partially 543 
neutralizing (pale yellow) and neutralizing mAbs (dark red) identified per each donor. The total 544 
number (N) of antibodies tested per individual is shown on top of each bar. (C) The graph shows 545 
the neutralization potency of each nAb tested once expressed as recombinant full-length IgG1. 546 
Dashed lines show different ranges of neutralization potency (500, 100 and 10 ng/mL). Dots were 547 
colored based on their neutralization potency and were classified as weakly neutralizing (>500 548 
ng/mL; pale orange), medium neutralizing (100 – 500 ng/mL; orange), highly neutralizing (10 – 100 549 










antibodies tested per individual is shown on top of each graph. A COVID-19 convalescent plasma 551 
and an unrelated plasma were used as positive and negative control respectively in all the assays. 552 
 553 
Figure 3. Functional characterization of potent SARS-CoV-2 S-protein specific nAbs  554 
(A – B - C) Graphs show binding curves to the S-protein in its trimeric conformation, S1-domain and 555 
S2-domain. Mean ± SD of technical triplicates are shown. Dashed lines represent the threshold of 556 
positivity; (D – F) Neutralization curves for selected antibodies were shown as percentage of viral 557 
neutralization against the authentic SARS-CoV-2 wild type (D), D614G variant (E) and the 558 
emerging variant B.1.1.7 (F). Data are representative of technical triplicates. A neutralizing COVID-559 
19 convalescent plasma and an unrelated plasma were used as positive and negative control 560 
respectively. (G – I) Neutralization potency of fourteen selected antibodies against the authentic 561 
SARS-CoV-2 wild type (G), D614G variant (H) and the emerging variant B.1.1.7 (I). Dashed lines 562 
show different ranges of neutralization potency (500, 100 and 10 ng/mL). In all graphs selected 563 
antibodies are shown in dark red, pink, gray and light blue based on their ability to recognize the 564 
SARS-CoV-2 S1-RBD, S1-domain, S-protein trimer only and S2-domain respectively.  565 
 566 
Figure 4. Identification of four different sites of pathogen vulnerability on the S-protein surface  567 
(A) Representative cytometer peaks per each of the four antibody groups are shown. Positive 568 
(beads conjugated with only primary labelled antibody) and negative (un-conjugated beads) 569 
controls are shown as green and red peaks respectively. Competing and not-competing nAbs are 570 
shown in blue and gray peaks respectively. (B) The heatmap shows the competition matrix 571 
observed among the 14 nAbs tested. Threshold of competition was set at 50% of fluorescent signal 572 
reduction. A speculative representation of the vulnerability sites is shown on the S-protein surface. 573 
 574 
Figure 5 Heavy and light chain analyses of selected nAbs  575 
(A – B) Bar graphs show the heavy and light chains usage for neutralizing antibodies against 576 
SARS-CoV-2 in the public repertoire compared to the antibodies identified in this study. Our and 577 
public antibodies are shown in dark and light colors respectively. (C – D) The heavy and light chain 578 










and distribution plot respectively. (E) The heatmap shows the frequency of heavy and light chain 580 
pairing for SARS-CoV-2 neutralizing human monoclonal antibodies already published. The number 581 
within the heatmap cells represent the amount of nAbs described in this manuscript showing 582 
already published (colored cells) or novel heavy and light chain rearrangements (blank cells). 583 
 584 
Figure 6. EM epitope mapping of RBD mAbs  585 
(A) Negative stain for J08, I14 and F05 in complex with the S-protein. 200 nm scale bar is shown; 586 
(B) Figures show the binding of J08 (blue), I14 (green) and F05 (red) to the SARS-CoV-2 S-protein 587 
RBD. 588 
 589 
Figure 7. Prophylactic and therapeutic efficacy of J08-MUT in the golden Syrian hamster model of 590 
SARS-CoV-2 infection  591 
(A) Schematic representation and timelines of prophylactic and therpaeutic studies performed in 592 
golden Syrian hamster. (B) The figure shows the prophylactic impact of J08-MUT at three different 593 
concentrations (4 – 1 – 0.25 mg/kg) on body weight loss change (C). The figure shows the 594 
therapeutic impact of J08-MUT at 4 mg/kg on body weight loss change. (D – F) The figures show 595 
the lung viral titer at day 3 (D) and the detection of human antibodies in hamster sera at day 3 (E) 596 
and day 8 (F) in the prophylactic study. (G – I) The figures show the lung viral titer at day 3 (G) and 597 
the detection of human antibodies in hamster sera at day 3 (H) and day 12 (I) in the therapeutic 598 
study. Statistically differences were calculated with two-way analysis of variance (ANOVA) for body 599 
weight change and with a nonparametric Mann–Whitney t-test for the lung viral titer. Significances 600 
are shown as * (p≤0.05), ** (p≤0.01), *** (p≤0.001) and **** (p≤0.0001).  601 
 602 
Figure S1. Gating strategy for single cell sorting and monoclonal antibodies screening for S-protein 603 
S1 + S2 subunits binding and neutralization of binding (NoB) activity, related to Figure 2 604 
(A) Starting from top left to the right panel, the gating strategy shows: Live/Dead; Morphology; 605 
CD19+ B cells; CD19+CD27+IgD-; CD19+CD27+IgD-IgM-; CD19+CD27+IgD-IgM-S-protein+ B cells. 606 
(B) The graph shows supernatants tested for binding to the SARS-CoV-2 S-protein S1 + S2 607 










Darker dots represent mAbs which bind to the S1 + S2 while light yellow dots represent mAbs 609 
which do not bind. (B) The graph shows supernatants tested by NoB assay. Threshold of positivity 610 
has been set as 50% of binding neutralization (dotted line). Dark blue dots represent mAbs able to 611 
neutralize the binding between SARS-CoV-2 and receptors on Vero E6 cells, while light blue dots 612 
represent non-neutralizing mAbs. 613 
 614 
Figure S2. Characterization and distribution of SARS-CoV-2 S-protein specific nAbs, related to 615 
Figure 2 616 
(A) The bar graph shows the distribution of nAbs binding to different S-protein domains. In dark 617 
red, light blue and gray are shown antibodies binding to the S1-domain, S2-domain and S-protein 618 
trimer respectively. The total number (N) of antibodies tested per individual is shown on top of each 619 
bar. (B) The bar graph shows the distribution of nAbs with different neutralization potencies. nAbs 620 
were classified as weakly neutralizing (>500 ng/mL; pale orange), medium neutralizing (100 – 500 621 
ng/mL; orange), highly neutralizing (10 – 100 ng/mL; dark orange) and extremely neutralizing (1 – 622 
10 ng/mL; dark red). The total number (N) of antibodies tested per individual is shown on top of 623 
each bar. 624 
 625 
Figure S3. Binding to S-protein receptor binding domain (RBD) and NoB activity of S1-RBD 626 
antibodies, related to Figure 3 627 
(A) Histograms show the ability of selected antibodies to bind the S-protein RBD. Gray histograms 628 
represent the negative control while colored histograms show tested antibodies. Percentage of 629 
positive and negative populations are denoted on each graph. (B) Neutralization of binding (NoB) 630 
curves for S1-RBD specific antibodies are shown as percentage of reduction of signal emitted by a 631 
fluorescently labled S-protein incubated with Vero E6 cells. Mean ± SD of technical duplicates are 632 
shown. Dashed lines represent the threshold of positivity; A neutralizing COVID-19 convalescent 633 
plasma and an unrelated plasma were used as positive and negative control respectively. 634 
 635 










Representative binding curves of selected antibodies to SARS-CoV-2 S-protein trimer. Different 637 
curve colors define the spike concentration used in the experiment. Kon, Koff and KD are denoted 638 
on each graph.  639 
 640 
Fig S5. Neutralization activity of selected nAbs against SARS-CoV-2, SARS-CoV and MERS-CoV 641 
pseudotypes, related to Figure 3 642 
(A – D) Graphs show the neutralizing activities of 14 selected nAbs with different SARS-CoV-2 S-643 
protein binding profiles against SARS-CoV-2, SARS-CoV-2 D614G, SARS-CoV and MERS-CoV 644 
pseudotypes respectively. Dashed lines represent the threshold of positivity. Mean ± SD of 645 
technical duplicates are shown. In all graphs selected antibodies are shown in dark red, pink, gray 646 
and light blue based on their ability to recognize the SARS-CoV-2 S1-RBD, S1-domain, S-protein 647 
trimer only and S2-domain respectively.  648 
 649 
Fig S6. Characterization of Fc-engineered candidate nAbs, related to Figure 7 650 
(A) the graph shows binding curves of J08, I14 and F05 MUT and WT to the FcγR2A. (B - C) 651 
graphs show binding curves of J08, I14 and F05 MUT and WT to the FcRn at pH 6.2 (B) and 7.4 652 
(C). (D - E) Graphs show the ADNP and ADNK induced by J08, I14 and F05 MUT and WT 653 
versions; all the experiments were run as technical duplicates. In every experiment a control 654 
antibody (CR3022) and an unrelated protein were used as positive and negative control 655 
respectively. (F – G - H) Graphs show binding curves to the S-protein in its trimeric conformation, 656 
S1-domain and S2-domain. Mean of technical triplicates are shown. (I – J - K) Neutralization curves 657 
against the authentic SARS-CoV-2 wild type, the D614G variant and the B.1.1.7 emerging variant 658 
for J08-MUT, I14-MUT and F05-MUT shown in blue, green and red respectively. Data are 659 
representative of technical triplicates.  660 
 661 
Fig S7. Autoreactivity assessment of selected SARS-CoV-2 candidate nAbs, related to Figure 7 662 
(A) Schematic representation of the indirect immunofluorescent assay for the screening of 663 
autoreactive nAb. (B) Single figures show the fluorescent signal detected per each sample tested in 664 









1:100). Three candidate nAbs were incubated on HEp-2 cells at a concentration of 100 µg/mL. 666 
Representative pictures of the scoring system are shown. Autoreactive samples are highlighted in 667 










STAR METHODS 669 
KEY RESOURCES TABLE 670 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies and Fluorophores     
CD19 V421 BD Biosciences Cat#562440 
IgM PerCP-Cy5.5 BD Biosciences Cat#561285 
CD27 PE BD Biosciences Cat#340425 
IgD-A700 BD Biosciences Cat#561302 
CD3 PE-Cy7 BioLegend Cat#300420 
CD14 PE-Cy7 BioLegend Cat#301814 
Streptavidin-PE  Thermo Fisher Cat#12-4317-87 
Goat Anti-Human IgA-UNLB Southern Biotech  Cat#2050-01 
Goat Anti-Human IgA-Alkaline Phosphatase Southern Biotech  Cat#2050-04 
Goat Anti-Human IgG-UNLB Southern Biotech  Cat#2040-01 
Bacterial and Virus Strains     
SARS-CoV-2 wild type EVAg GenBank: MT066156.1 
SARS-CoV-2 D614G EVAg GenBank: MT527178.1 





PBMCs and IgGs of donor PT-004 This paper N/A 
PBMCs and IgGs of donor PT-005 This paper N/A 
PBMCs and IgGs of donor PT-006 This paper N/A 
PBMCs and IgGs of donor PT-008 This paper N/A 
PBMCs and IgGs of donor PT-009 This paper N/A 
PBMCs and IgGs of donor PT-010 This paper N/A 
PBMCs and IgGs of donor PT-012 This paper N/A 
PBMCs and IgGs of donor PT-014 This paper N/A 
PBMCs and IgGs of donor PT-041 This paper N/A 
PBMCs and IgGs of donor PT-100 This paper N/A 
PBMCs and IgGs of donor PT-101 This paper N/A 
PBMCs and IgGs of donor PT-102 This paper N/A 
PBMCs and IgGs of donor PT-103 This paper N/A 
PBMCs and IgGs of donor PT-188 This paper N/A 
Chemicals, Peptides, and Recombinant Proteins     
Fetal Bovine Serum (FBS) Hyclone Sigma-Aldrich Cat#D2650 










RNaseOUT Recombinant Ribonuclease Inhibitor Thermo Fisher Cat#10777-019 
SuperScript IV Reverse Transcriptase Thermo Fisher Cat#18091200 
DEPC-Treated water Thermo Fisher Cat#AM9916 
dNTP Set (100 mM) Thermo Fisher Cat#10297018 
MgCl2   Magnesium Chloride 25mM Thermo Fisher Cat#AB0359 
Kapa Long Range Polymerase Sigma-Aldrich Cat#KK3005 
NEBuilder® HiFi DNA Assembly Master Mix New England BioLabs Cat#E2621X 
Q5® High-Fidelity DNA Polymerases New England BioLabs Cat#M0491L 
Expi293™ Expression Medium Thermo Fisher Cat#A1435101 
ExpiFectamine™ 293 Transfection Kit Thermo Fisher Cat#A14524 
Ultra Pure Bovine serum albumin (BSA) Thermo Fisher Cat#AM2618 
DMEM high Glucose Thermo Fisher Cat#11965092 
Ficoll-Paque™ PREMIUM Sigma-Aldrich Cat#GE17-5442-03 
MycoZap Plus-PR Lonza Cat#VZA2022 
IMDM with GlutaMAX Thermo Fisher Cat# 31980048 
Benzonase Nuclease Sigma-Aldrich Cat#70664-3 
IL-2 Recombinant Human Protein Thermo Fisher Cat#PHC0023 
IL-21 Recombinant Human Protein Thermo Fisher Cat#PHC0211 
Strep-Tactin DY488 IBA lifesciences Cat#2-1562-050 
Slide-A-Lyzer™ Dialysis Cassettes Thermo Fisher Cat#66003 
HiTrap Protein G HP column Cytiva Cat#17040503 
HisTrap FF Crude column Cytiva Cat#17528601 
SARS Coronavirus Spike Glycoprotein (S1) The Native Antigen Company Cat#REC31809 
SARS Coronavirus Spike Glycoprotein (S2) The Native Antigen Company Cat#REC31807 
Tween-20 VWR Cat#A4974.0250 
SARS Coronavirus Spike Glycoprotein (S1) The Native Antigen Company Cat#REC31806-500 
SARS Coronavirus Spike Glycoprotein (S2) The Native Antigen Company Cat#REC31807-500 
Alkaline Phosphatase Yellow (pNPP) Liquid 
Substrate System 
Sigma-Aldrich Cat#P7998 
Goat Anti-Human IgG-UNLB SouthernBiotech Cat#2040-01 
Critical Commercial Assays     
NOVA Lite Hep-2 ANA Kit Inova Diagnostics / Werfen Cat#066708100 
ELISA Starter Accessory Kit Bethyl Laboratories Cat#E101 
APEX Alexa Fluor 647 Antibody Labeling Kit Thermo Fisher Cat#A10475 
Pierce BCA Protein Assay Kit  Thermo Fisher Cat#23227 
Deposited Data     
Cloned and tested SARS-CoV-2-neutralizing 
antibodies 










Experimental Models: Cell Lines     
VERO E6 cell line ATCC Cat#CRL-1586 
Expi293F™ cells Thermo Fisher Cat#A14527 
3T3-msCD40L Cells NIH AIDS Reagent Program Cat#12535 
Oligonucleotides     
Single cell PCR Primer This paper N/A 
Random Hexamer Primer Thermo Fisher  Cat#SO142 
TAP forward primer 
(TTAGGCACCCCAGGCTTTAC) 
This paper N/A 
TAP forward primer 
(AGATGGTTCTTTCCGCCTCA) 
This paper N/A 
Recombinant DNA     
Human antibody expression vectors (IgG1, Igl, 
Igk) 
(Tiller et al., 2008) N/A 
Plasmid encoding SARS-CoV-2 S ectodomain 
(amino acids 1-1208 of SARS-CoV-2 S; 
GenBank: MN908947) 
(Wrapp et al., 2020) N/A 
Plasmid encoding SARS-CoV-2 RBD (amino 
acids 319 - 591 of SARS-CoV-2 S; GenBank: 
MN908947) 
Jason McLellan Lab N/A 
pCDNA3.1+-SARS-CoV-2 Spike from Wuhan-
Hu-1 isolate (Genbank MN908947.3) codon 
optimised   
This paper pCDNA-S2  
pCAGGS-SARS-CoV-2 Spike from Wuhan-Hu-1 
isolate (Genbank MN908947.3) encoding D614G 
mutation  and codon optimised   
This paper pCAGGS-S2 D614G  
pCAGGS-SARS1 Spike protein codon optimised  (Carnell et al., 2017) pCAGGS-S1  
pCAGGS-MERS Spike protein codon optimised  (Grehan et al., 2015) pCAGGS-MERS  
pCSFLW Firefly luciferase encoding plasmid  (Carnell et al., 2015) pCSFLW  
p8.91 HIV Gag/Pol-encoding plasmid   (Carnell et al., 2015) p8.91  
Software and Algorithms     
Prism 8 GraphPad 
https://www.graphpad.com
/ 
FlowJo 10.5.3 FlowJo, LLC https://www.flowjo.com 




MultiQC 1.9 MultiQC https://multiqc.info/ 











MiXCR MI Lanoratory 
https://mixcr.readthedocs.i
o/en/master/index.html  
NumPy  NumPy https://numpy.org/  
Python 3.7.4 Python Software Foundation https://www.python.org/  
Other     
BD FACS Aria III Cell Sorter BD Biosciences 
https://www.bdbiosciences
.com  
BD FACS Canto II  BD Biosciences 
https://www.bdbiosciences
.com  
Leica DMI-microscope Leica Biosystem 
https://www.leica-
microsystems.com 
LUNA-II Automated Cell Counter Logo Biosystems https://logosbio.com  
Qubit Fluorometric Quantification Thermo Fisher 
https://www.thermofisher.c
om  
ÄKTA go Cytiva Lifesciences 
https://www.cytivalifescien
ces.com 
GloMax Luminometer Promega https://ita.promega.com  
Varioskan LUX multimode microplate reader Thermo Fisher 
https://www.thermofisher.c
om  










RESOURCE AVAILABILITY 672 
Lead Contact 673 
Further information and requests for resources and reagents should be directed to and will be 674 
fulfilled by the Lead Contact, Rino Rappuoli (rino.r.rappuoli@gsk.com). 675 
 676 
Materials Availability 677 
Reasonable amounts of antibodies will be made available by the Lead Contact upon request under 678 
a Material Transfer Agreement (MTA) for non-commercial usage. 679 
 680 
Data and Code Availability 681 
Nucleotide and amino acidic sequences of all SARS-CoV-2-neutralizing antibodies were deposited 682 
in the Italian patent applications n. 102020000015754 filed on June 30th 2020 and 683 
102020000018955 filed on August 3rd 2020. Nucleotide sequences of all SARS-CoV-2-neutralizing 684 
antibodies were deposited at GenBank. 685 
 686 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 687 
Enrollment of SARS-COV-2 convalescent donors and human sample collection  688 
This work results from a collaboration with the National Institute for Infectious Diseases, IRCCS – 689 
Lazzaro Spallanzani Rome (IT) and Azienda Ospedaliera Universitaria Senese, Siena (IT) that 690 
provided samples from SARS-CoV-2 convalescent donors, of both sexes, who gave their written 691 
consent. The study was approved by local ethics committees (Parere 18_2020 in Rome and Parere 692 
17065 in Siena) and conducted according to good clinical practice in accordance with the 693 
declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997). This 694 
study was unblinded and not randomized.  695 










METHOD DETAILS 697 
Single cell sorting of SARS-CoV-2 S-protein+ memory B cells from COVID-19 convalescent donors 698 
Blood samples were screened for SARS-CoV-2 RNA and for antibodies against HIV, HBV and 699 
HCV. Peripheral blood mononuclear cells (PBMCs) were isolated from heparin-treated whole blood 700 
by density gradient centrifugation (Ficoll-Paque™ PREMIUM, Sigma-Aldrich). After separation, 701 
PBMC were stained with Live/Dead Fixable Aqua (Invitrogen; Thermo Scientific) in 100 µL final 702 
volume diluted 1:500 at room temperature RT. After 20 min incubation cells were washed with PBS 703 
and unspecific bindings were saturated with 50 µL of 20% normal rabbit serum (Life technologies) 704 
in PBS . Following 20 min incubation at 4°C cells were washed with PBS and stained with SARS-705 
CoV-2 S-protein labeled with Strep-Tactin®XT DY-488 (iba-lifesciences cat# 2-1562-050) for 30 706 
min at 4°C. After incubation the following staining mix was used CD19 V421 (BD cat# 562440), IgM 707 
PerCP-Cy5.5 (BD cat# 561285), CD27 PE (BD cat# 340425), IgD-A700 (BD cat# 561302), CD3 708 
PE-Cy7 (BioLegend cat# 300420), CD14 PE-Cy7 (BioLegend cat# 301814), CD56 PE-Cy7 709 
(BioLegend cat# 318318) and cells were incubated at 4°C for additional 30 min. Stained MBCs 710 
were single cell-sorted with a BD FACS Aria III (BD Biosciences) into 384-well plates containing 711 
3T3-CD40L feeder cells and were incubated with IL-2 and IL-21 for 14 days as previously 712 
described (Huang et al., 2013).  713 
 714 
Expression and purification of SARS-CoV-2 S-protein prefusion trimer and receptor binding domain 715 
Plasmid encoding SARS-CoV-2 S-2P construct (Wrapp et al., 2020) and S-protein RBD 716 
(generously provided by Jason S. McLellan) were transiently transfected at 1 µg/mL culture into 717 
Expi293F™ cells (Thermo Fisher) using ExpiFectamine™ 293 Reagent. Cells were grown for six 718 
days at 37 °C with 8% CO2 shaking 125 rpm according to the manufacturer’s protocol (Thermo 719 
Fisher); ExpiFectamine™ 293 Transfection Enhancers 1 and 2 were added 16 to 18 hours post-720 
transfection to boost transfection, cell viability, and protein expression. Cell cultures were 721 
harvested three and six days after transfection. Cells were separated from the medium by 722 
centrifugation (1,100 g for 10 min at 24°C). Collected supernatants were then pooled and clarified 723 










Chromatography was conducted at room temperature using the ÄKTA go purification system from 725 
GE Healthcare Life Sciences. Expressed proteins were purified by using an immobilized metal 726 
affinity chromatography (FF Crude) followed by dialysis into final buffer. Specifically, the filtrated 727 
culture supernatant was purified with a 5 mL HisTrap FF Crude column (GE Healthcare Life 728 
Sciences) previously equilibrated in Buffer A (20 mM NaH2PO4, 500 mM NaCl + 30 mM imidazol 729 
pH 7.4). 730 
The flow rate for all steps of the HisTrap FF Crude column was 5 mL/min. The culture supernatant 731 
of spike and RBD cell culture was applied to a single 5 mL HisTrap FF Crude column. The column 732 
was washed in Buffer A for 4 column volumes (CV) with the all 4 CV collected as the column wash. 733 
Recombinant proteins were eluted from the column applying a first step elution of 4 CV of 50% 734 
Buffer B (20 mM NaH2PO4, 500 mM NaCl + 500 mM imidazol pH 7.4) and a second step elution of 735 
2 CV of 100% Buffer B. Elution steps were collected in 1 fractions of 1 mL each. Eluted fractions 736 
were analyzed by SDS-PAGE and appropriate fractions containing recombinant proteins were 737 
pooled. Final pools were dialyzed against phosphate buffered saline (PBS) pH 7.4 using Slide-A-738 
Lyzer™ G2 Dialysis Cassette 3.5K (Thermo Scientific) overnight at 4°C. The dialysis buffer used 739 
was at least 200 times the volume of the sample. 740 
The final protein concentration was determined by measuring the A520 using the Pierce™ BCA 741 
protein assay kit (Thermo Scientific™ ). Final protein was dispensed in aliquots of 0.5 ml each and 742 
stored at -80°C. 743 
 744 
ELISA assay with S1 and S2 subunits of SARS-CoV-2 S-protein 745 
The presence of S1- and S2-binding antibodies in culture supernatants of monoclonal S-protein-746 
specific memory B cells was assessed by means of an ELISA implemented with the use of a 747 
commercial kit (ELISA Starter Accessory Kit, Catalogue No. E101; Bethyl Laboratories). Briefly, 748 
384-well flat-bottom microtiter plates (384 well plates, Microplate Clear, Greiner Bio-one) were 749 
coated with 25 µL/well of antigen (1:1 mix of S1 and S2 subunits, 1 µg/mL each; The Native 750 
Antigen Company, Oxford, United Kingdom) diluted in coating buffer (0.05 M carbonate-751 










times with 100 µL/well washing buffer (50 mM Tris Buffered Saline (TBS) pH 8.0, 0.05% Tween-20) 753 
and saturated with 50 µL/well blocking buffer containing Bovine Serum Albumin (BSA) (50 mM TBS 754 
pH 8.0, 1% BSA, 0.05% Tween-20) for 1 hour (h) at 37°C. After further washing, samples diluted 755 
1:5 in blocking buffer were added to the plate. Blocking buffer was used as a blank. After an 756 
incubation of 1 h at 37°C, plates were washed and incubated with 25 µL/well secondary antibody 757 
(horseradish peroxidase (HRP)-conjugated goat anti-human IgG-Fc Fragment polyclonal antibody, 758 
diluted 1:10,000 in blocking buffer, Catalogue No. A80-104P; (Bethyl Laboratories) for 1 h at 37°C. 759 
After three washes, 25 µL/well TMB One Component HRP Microwell Substrate (Bethyl 760 
Laboratories) was added and incubated 10–15 minutes at RT in the dark. Color development was 761 
terminated by addition of 25 µL/well 0.2 M H2SO4. Absorbance was measured at 450 nm in a 762 
Varioskan Lux microplate reader (Thermo Fisher Scientific). Plasma from COVID-19 convalescent 763 
donors (Andreano et al., 2020) and unrelated plasma were used as positive and negative control 764 
respectively. The threshold for sample positivity was set at twice the optical density (OD) of the 765 
blank. 766 
 767 
ELISA assay with SARS-CoV-2 S-protein prefusion trimer and S1 – S2 subunits 768 
ELISA assay was used to detect SARS-CoV-2 S-protein specific mAbs and to screen plasma from 769 
SARS-CoV-2 convalescent donors. 384-well plates (384 well plates, microplate clear; Greiner Bio-770 
one) were coated with 3 µg/mL of streptavidin (Thermo Fisher) diluted in coating buffer (0.05 M 771 
carbonate-bicarbonate solution, pH 9.6) and incubated at RT overnight. Plates were then coated 772 
with SARS-CoV-2 S-protein, S1 or S2 domains at 3 µg/mL and incubated for 1h at RT. 50 µL/well 773 
of saturation buffer (PBS/BSA 1%) was used to saturate unspecific binding and plates were 774 
incubated at 37°C for 1h without CO2. For the first round of screening, supernatants were diluted 775 
1:5 in PBS/BSA 1%/Tween20 0.05% in 25 µL/well final volume and incubated for 1h at 37°C 776 
without CO2. For purified antibodies, and to assess EC50, mAbs were tested at a starting 777 
concentration of 5 µg/mL and diluted step 1:2 in PBS/BSA 1%/Tween20 0.05% in 25 µL/well final 778 
volume for 1h at 37°C without CO2. 25 µL/well of alkaline phosphatase-conjugated goat anti-human 779 










washed three times between each step with PBS/BSA 1%/Tween20 0.05%. pNPP (p-nitrophenyl 781 
phosphate) (Sigma-Aldrich) was used as soluble substrate to detect SARS-CoV-2 S-protein, S1 or 782 
S2 specific mAbs and the final reaction was measured by using the Varioskan Lux Reader (Thermo 783 
Fisher Scientific) at a wavelength of 405 nm. Plasma from COVID-19 convalescent donors 784 
(Andreano et al., 2020) and unrelated plasma were used as positive and negative control 785 
respectively. Samples were considered as positive if OD at 405 nm (OD405) was twice the blank. 786 
 787 
SARS-CoV-2 virus and cell infection 788 
African green monkey kidney cell line Vero E6 cells (American Type Culture Collection [ATCC] 789 
#CRL-1586) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) - high glucose 790 
(Euroclone, Pero, Italy) supplemented with 2 mM L- Glutamine (Lonza, Milano, Italy), penicillin (100 791 
U/mL) - streptomycin (100 µg/mL) mixture (Lonza, Milano, Italy) and 10% Foetal Bovine Serum 792 
(FBS) (Euroclone, Pero, Italy). Cells were maintained at 37°C, in a 5% CO2 humidified environment 793 
and passaged every 3-4 days. 794 
Wild type SARS-CoV-2 (SARS-CoV-2/INMI1-Isolate/2020/Italy: MT066156), D614G (SARS-CoV-795 
2/human/ITA/INMI4/2020, clade GR, D614G (S): MT527178) and B.1.1.7 (INMI-118 GISAID 796 
accession number EPI_ISL_736997) viruses were purchased from the European Virus Archive 797 
goes Global (EVAg, Spallanzani Institute, Rome)or received from the Spallanzani Institute, Rome. 798 
For virus propagation, sub-confluent Vero E6 cell monolayers were prepared in T175 flasks 799 
(Sarstedt) containing supplemented D-MEM high glucose medium. For titration and neutralization 800 
tests of SARS-CoV-2, Vero E6 were seeded in 96-well plates (Sarstedt) at a density of 1.5 x 104 801 
cells/well the day before the assay. 802 
 803 
Neutralization of Binding (NoB) Assay 804 
To study the binding of the SARS-CoV-2 S-protein to cell-surface receptor(s) we developed an 805 
assay to assess recombinant S-protein specific binding to target cells and neutralization thereof. To 806 
this aim the stabilized S-protein was coupled to Streptavidin-PE (eBioscience # 12-4317-87, 807 










cytometry. The stabilized S-protein bound Vero E6 cells with high affinity (data not shown). To 809 
assess the content of neutralizing antibodies in sera or in B-cell culture supernatants, two 810 
microliters of SARS-CoV-2 Spike-Streptavidin-PE at 5 - 10 µg/mL in PBS-5%FCS were mixed with 811 
two microliters of various dilutions of sera or B-cell culture supernatants in U bottom 96-well plates. 812 
After incubation at 37°C for 1 hr, 30 x 103 Vero E6 cells suspended in two microliters of PBS 5% 813 
FCS were added and incubated for additional 45 min at 4°C. Non-bound protein and antibodies 814 
were removed and cell-bound PE-fluorescence was analyzed with a FACS Canto II flow cytometer 815 
(Becton Dickinson). Data were analyzed using the FlowJo data analysis software package 816 
(TreeStar, USA). The specific neutralization was calculated as follows: NoB (%) = 1 – (Sample MFI 817 
value – background MFI value) / (Negative Control MFI value – background MFI value). Plasma 818 
from COVID-19 convalescent donors (Andreano et al., 2020) and unrelated plasma were used as 819 
positive and negative control respectively. 820 
 821 
Single cell RT-PCR and Ig gene amplification 822 
From the original 384-well sorting plate, 5 µL of cell lysate was used to perform RT-PCR. Total 823 
RNA from single cells was reverse transcribed in 25 µL of reaction volume composed by 1 µL of 824 
random hexamer primers (50 ng/µL), 1 µL of dNTP-Mix (10 mM), 2 µL 0.1 M DTT, 40 U/µL RNAse 825 
OUT, MgCl2 (25 mM), 5x FS buffer and Superscript IV reverse transcriptase (Invitrogen). Final 826 
volume was reached by adding nuclease-free water (DEPC). Reverse transcription (RT) reaction 827 
was performed at 42°C/10’, 25°C/10’, 50°C/60’ and 94°/5’. Heavy (VH) and light (VL) chain 828 
amplicons were obtained via two rounds of PCR. All PCR reactions were performed in a nuclease-829 
free water (DEPC) in a total volume of 25 µL/well. Briefly, 4 µL of cDNA were used for the first 830 
round of PCR (PCRI). PCRI-master mix contained 10 µM of VH and 10 µM VL primer-mix ,10mM 831 
dNTP mix, 0.125 µL of Kapa Long Range Polymerase (Sigma), 1.5 µL MgCl2 and 5 µL of 5x Kapa 832 
Long Range Buffer. PCRI reaction was performed at 95°/3’, 5 cycles at 95°C/30’’, 57°C/30’’, 833 
72°C/30’’ and 30 cycles at 95°C/30’’, 60°C/30’’, 72°C/30’’ and a final extension of 72°/2’. All nested 834 
PCR reactions (PCRII) were performed using 3.5 µL of unpurified PCRI product using the same 835 










according to manufacture instructions. Samples were eluted with 30 µL nuclease-free water 837 
(DEPC) into 96-well plates and quantify by.  838 
 839 
Cloning of variable region genes and recombinant antibody expression in transcriptionally active 840 
PCR  841 
Vector digestions were carried out with the respective restriction enzymes AgeI, SalI and Xho as 842 
previously described (Tiller et al., 2008, Wardemann and Busse, 2019). Briefly, 75 ng of IgH, Igλ 843 
and Igκ purified PCRII products were ligated by using the Gibson Assembly NEB into 25 ng of 844 
respective human Igγ1, Igκ and Igλ expression vectors. The reaction was performed into 5 µL of 845 
total volume. Ligation product was 10-fold diluted in nuclease-free water (DEPC) and used as 846 
template for transcriptionally active PCR (TAP) reaction which allowed the direct use of linear DNA 847 
fragments for in vitro expression. The entire process consists of one PCR amplification step, using 848 
primers to attach functional promoter (human CMV) and terminator sequences (SV40) onto the 849 
fragment PCRII products. TAP reaction was performed in a total volume of 25 µL using 5 µL of Q5 850 
polymerase (NEB), 5 µL of GC Enhancer (NEB), 5 µL of 5X buffer,10 mM dNTPs, 0.125 µL of 851 
forward/reverse primers and 3 µL of ligation product. TAP reaction was performed by using the 852 
following cycles: 98°/2’, 35 cycles 98°/10’’, 61°/20’’, 72°/1’ and 72°/5’ as final extention step. TAP 853 
products were purified under the same PCRII conditions, quantified by Qubit Fluorometric 854 
Quantitation assay (Invitrogen) and used for transient transfection in Expi293F cell line using 855 
manufacturing instructions.  856 
 857 
Flask expression and purification of human monoclonal antibodies 858 
Expi293F™ cells (Thermo Fisher) were transiently transfected with plasmids carrying the antibody 859 
heavy chain and the light chains with a 1:2 ratio. Cells were grown for six days at 37 °C with 8% 860 
CO2 shaking at 125 rpm according to the manufacturer’s protocol (Thermo Fisher); 861 
ExpiFectamine™ 293 transfection enhancers 1 and 2  were added 16 to 18 hours post-transfection 862 
to boost cell viability and protein expression. Cell cultures were harvested three and six days after 863 










Supernatants collected were then pooled and clarified by centrifugation (3000 g for 15 min, 4°C) 865 
followed by filtration through a 0.45 µm filter. Chromatography was conducted at room temperature 866 
using the ÄKTA go purification system from GE Healthcare Life Sciences. Affinity chromatography 867 
was used to purify expressed monoclonal antibodies using an immobilized protein G column able 868 
to bind to Fc region. Specifically, filtrated culture supernatants were purified with a 1 mL HiTrap 869 
Protein G HP column (GE Healthcare Life Sciences) previously equilibrated in Buffer A (0.02 M 870 
NaH2PO4 pH 7). The flow rate for all steps of the HiTrap Protein G HP column was  1 mL/min. The 871 
culture supernatant for every monoclonal antibody cell culture was applied to a single 1 mL HiTrap 872 
Protein G HP column. The column was equilibrated in Buffer A for at least 6 column volumes (CV) 873 
which was collected as column wash. Each monoclonal antibody was eluted from the column 874 
applying a step elution of 6 CV of Buffer B (0.1 M glycine-HCl, pH 2.7). Elution steps were collected 875 
in 1 fractions of 1 mL each. Eluted fractions were analyzed by non-reducing SDS-PAGE and 876 
fractions showing the presence of IgG were pooled together.  Final pools was dialyzed in PBS 877 
buffer pH 7.4 using Slide-A-Lyzer™ G2 Dialysis Cassette 3.5K (Thermo Scientific) overnight at 4°C. 878 
The dialysis buffer used was at least 200 times the volume of the sample. For each antibody 879 
purified the concentration was determined by measuring the A520 using Pierce™ BCA Protein 880 
Assay Kit (Thermo Scientific). All the purified antibodies were aliquoted and stored at -80°C. 881 
 882 
Viral propagation and titration  883 
The SARS-CoV-2 virus was propagated in Vero E6 cells cultured in DMEM high Glucose 884 
supplemented with 2% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin. Cells were seeded at a 885 
density of 1x106 cells/mL in T175 flasks and incubated at 37°C, 5% CO2 for 18 - 20 hours. The sub-886 
confluent cell monolayer was then washed twice with sterile Dulbecco’s PBS (DPBS). Cells were 887 
inoculated with 3,5 mL of the virus properly diluted in DMEM 2% FBS at a multiplicity of infection 888 
(MOI) of 0.001, and incubated for 1h at 37°C in a humidified environment with 5% CO2. At the end 889 
of the incubation, 50 mL of DMEM 2% FBS were added to the flasks. The infected cultures were 890 
incubated at 37°C, 5% CO2 and monitored daily until approximately 80-90% of the cells exhibited 891 










for 8 minutes to allow removal of cell debris, aliquoted and stored at -80°C as the harvested viral 893 
stock. Viral titers were determined in confluent monolayers of Vero E6 cells seeded in 96-well 894 
plates using a 50% tissue culture infectious dose assay (TCID50). Cells were infected with serial 895 
1:10 dilutions (from 10-1 to 10-11) of the virus and incubated at 37°C, in a humidified atmosphere 896 
with 5% CO2. Plates were monitored daily for the presence of SARS-CoV-2 induced CPE for 4 897 
days using an inverted optical microscope. The virus titer was estimated according to Spearman-898 
Karber formula (Kundi, 1999) and defined as the reciprocal of the highest viral dilution leading to at 899 
least 50% CPE in inoculated wells. 900 
 901 
SARS-CoV-2 authentic virus neutralization assay  902 
All SARS-CoV-2 authentic virus neutralization assays were performed in the biosafety level 3 903 
(BSL3) laboratories at Toscana Life Sciences in Siena (Italy) and Vismederi Srl, Siena (Italy). BSL3 904 
laboratories are approved by a Certified Biosafety Professional and are inspected every year by 905 
local authorities. The neutralization activity of culture supernatants from monoclonal was evaluated 906 
using a CPE-based assay as previously described (Manenti et al., 2020). S-protein-specific 907 
memory B cells produced antibodies were initially evaluated by means of a qualitative live-virus 908 
based neutralization assay against a one-point dilution of the samples. Supernatants were mixed in 909 
a 1:3 ratio with a SARS-CoV-2 viral solution containing 25 TCID50 of virus (final volume: 30 µL). 910 
After 1 hour incubation at 37°C, 5% CO2, 25 µL of each virus-supernatant mixture was added to the 911 
wells of a 96-well plate containing a sub-confluent Vero E6 cell monolayer. Following a 2-hours 912 
incubation at 37°C, the virus-serum mixture was removed and 100 µl of DMEM 2% FBS were 913 
added to each well. Plates were incubated for 3 days at 37°C in a humidified environment with 5% 914 
CO2, then examined for CPE by means of an inverted optical microscope. Absence or presence of 915 
CPE was defined by comparison of each well with the positive control (plasma sample showing 916 
high neutralizing activity of SARS-CoV-2 in infected Vero E6 cells (Andreano et al., 2020) and 917 
negative control (human serum sample negative for SARS-CoV-2 in ELISA and neutralization 918 
assays). Following expression as full-length IgG1 recombinant antibodies were quantitatively 919 










emerging variants. The assay was performed as previously described but using a viral titer of 100 921 
TCID50. Antibodies were prepared at a starting concentration of 20 µg/mL and diluted step 1:2. 922 
Technical triplicates were performed for each experiment.  923 
 924 
Production and titration of SARS-CoV-2 pseudotyped lentiviral reporter particles  925 
Pseudotype stocks were prepared by FuGENE-HD (Promega) co-transfection of HEK293T/17 with 926 
SARS-CoV-2 spike pcDNA3.1 + expression plasmid, HIV gag-pol p8.91 plasmid and firefly 927 
luciferase expressing plasmid pCSFLW in a 1:0.8:1.2 ratio. 2 x 106 cells/cm2 were plated 24h prior 928 
to transfection in 10cm cell culture dishes. 48 and 72h post transfection, pseudotype-containing 929 
culture medium was harvested and filtered thought a 0.45um syringe filter to clear cell debris. 930 
Aliquots were stored at -80°C. Titration assays were performed by transduction of HEK293T/17 931 
cells pre-transfected with ACE2 and TMPRRS2 plasmids to calculate the viral titer and infectious 932 
dose (PV input) for neutralization assays. SARS-CoV-2 D614G pseudotype was produced using 933 
the same procedure as described above. SARS-1 pseudotype was produced in a 1:0.5:0.8 ratio. 934 
MERS-pseudotype was produced as previously described (Grehan et al., 2015). 935 
 936 
SARS-CoV-2 pseudotyped lentivirus neutralization assay 937 
The potency of the neutralizing mAbs was assessed using lentiviral particles expressing SARS-938 
CoV-2 spike protein on their surface and containing firefly luciferase as marker gene for detection 939 
of infection. Briefly, 2 x 106 HEK293T cells were pre-transfected in a 10 cm dish the day before the 940 
neutralization assay with ACE2 and TMPRSS2 plasmids in order to be used as optimal target cells 941 
for SARS-CoV-2 PV entry. In a 96-well plate mAbs were 2-fold serially diluted in duplicate in culture 942 
medium (DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin) 943 
starting at 20 µg/mL in a total volume of 100 µL. 1x106 RLU of SARS-CoV-2 pseudotyped lentiviral 944 
particles were added to each well and incubated at 37ºC for 1h. Each plate included PV plus cell 945 
only (virus control) and cells only (background control). 1 x 104 pre-transfected HEK293T cells 946 
suspended in 50 µL complete media were added per well and incubated for 48h at 37°C and 5% 947 
CO2. Firefly luciferase activity (luminescence) was measured using the Bright-Glo assay system 948 










points were converted to a percentage neutralization value, whereby 100% neutralization equals 950 
the mean cell only RLU value control and 0% neutralization equals the mean PV only RLU value 951 
control. The normalized data was then plotted using Prism 8 (GraphPad) on a neutralization 952 
percentage scale and a NT50 value calculated, using the non-linear regression analysis. Plasma 953 
from COVID-19 convalescent donors showing neutralization activity against SARS-CoV-2 954 
(Andreano et al., 2020) were also assessed in this assay. 955 
 956 
Characterization of SARS-CoV-2 RBD-Antibodies binding by Flow cytometry 957 
Flow cytometry analysis was performed to define antibodies interaction with S-protein-receptor-958 
binding domain (RBD). Briefly, APEX™ Antibody Labeling Kits (Invitrogen) was used to conjugate 959 
20 µg of selected antibodies to Alexa fluor 647, according to the manufacturer instructions. To 960 
assess the ability of each antibody to bind the RBD domain, 1 mg of magnetic beads (Dynabeads™ 961 
His-Tag, Invitrogen) were coated with 70 µg of histidine tagged RBD, and then  20 µg/mL of each 962 
labelled antibody were incubated with 40 µg/mL of beads-bound RBD for 1 hour on ice. Then, 963 
samples were washed with 200 µL of Phosphate-buffered saline (PBS), resuspended in 150 µL of 964 
PBS and assessed with a FACS Canto II flow cytometer (Becton Dickinson). Results were 965 
analyzed by FlowJo (version 10). 966 
 967 
Flow Cytometry-Based S-protein Competition assay 968 
Antibodies specificity to bind SARS-CoV-2 S-protein and their possible competition was analyzed 969 
performing a Flow cytometer-based assay. To this aim, 200 µg of stabilized histidine tagged S-970 
protein were coated with 1 mg of magnetic beads (Dynabeads™ His-Tag, Invitrogen). 20 µg of each 971 
antibody were labelled with Alexa fluor 647 working with the APEX™ Antibody Labeling Kits 972 
(Invitrogen). To test competitive binding profiles of the antibody panel selected, beads-bound S-973 
protein (40 µg/mL) were pre-incubated with unlabeled antibodies (40 µg/mL) for 1 hour on ice. 974 
Then, each set of the beads-antibody complexes were washed with PBS and separately incubated 975 
with each labelled antibody (20 µg/mL) for 1 hour on ice. After incubation, the mix Beads-antibodies 976 
was washed, resuspended in 150 µL of PBS and analyzed using FACS Canto II flow cytometer 977 










were used as positive and negative control, respectively. Population gating and analysis was 979 
carried out using FlowJo (version 10). 980 
 981 
Antigen-specific FcγR binding 982 
Fluorescently coded microspheres were used to profile the ability of selected antibodies to interact 983 
with Fc receptors (Boudreau et al., 2020). The antigen of interest (SARS –CoV-2 S-protein RBD) 984 
was covalently coupled to different bead sets via primary amine conjugation. The beads were 985 
incubated with diluted antibody (diluted in PBS), allowing “on bead” affinity purification of antigen-986 
specific antibodies. The bound antibodies were subsequently probed with tetramerized 987 
recombinant human FcγR2A and FcRN and analyzed using Luminex. The data is reported as the 988 
median fluorescence intensity of PE for a specific bead channel. 989 
 990 
Antibody-dependent neutrophil phagocytosis  991 
Antibody-dependent neutrophil phagocytosis (ADNP) assesses the ability of antibodies to induce 992 
the phagocytosis of antigen-coated targets by primary neutrophils. The assay was performed as 993 
previously described (Karsten et al., 2019, Boudreau et al., 2020). Briefly, fluorescent streptavidin-994 
conjugated polystyrene beads were coupled to biotinylated SARS-CoV-2 Spike trimer. Diluted 995 
antibody (diluted in PBS) was added, and unbound antibodies were washed away. The 996 
antibody:bead complexes are added to primary neutrophils isolated from healthy blood donors 997 
using negative selection (StemCell EasySep Direct Human Neutrophil Isolation Kit), and 998 
phagocytosis was allowed to proceed for 1 hour. The cells were then washed and fixed, and the 999 
extent of phagocytosis was measured by flow cytometry. The data is reported as a phagocytic 1000 
score, which considers the proportion of effector cells that phagocytosed and the degree of 1001 
phagocytosis. Each sample is run in biological duplicate using neutrophils isolated from two distinct 1002 
donors. The mAb were tested for ADNP activity at a range of 30 µg/mL to 137.17 ng/mL. 1003 
 1004 
Antibody-dependent NK cell activation 1005 
Antibody-dependent NK cell activation (ADNKA) assesses antigen-specific antibody-mediated NK 1006 










(Boudreau et al., 2020). Stabilized SARS-CoV-2 Spike trimer was used to coat ELISA plates, which 1008 
were then washed and blocked. Diluted antibody (diluted in PBS) was added to the antigen coated 1009 
plates, and unbound antibodies were washed away. NK cells, purified from healthy blood donor 1010 
leukopaks using commercially available negative selection kits (StemCell EasySep Human NK Cell 1011 
Isolation Kit) were added, and the levels of IFN-γ was measured after 5 hours using flow cytometry. 1012 
The data is reported as the percent of cells positive for IFN-γ. Each sample is tested with at least 1013 
two different NK cell donors, with all samples tested with each donor. The monoclonal antibodies 1014 
were tested for ADNKA activity at a range of 20 µg/mL to 9.1449 ng/mL. 1015 
 1016 
Affinity evaluation of SARS-CoV-2 neutralizing antibodies 1017 
Anti-Human IgG Polyclonal Antibody (Southern Biotech 2040-01) was immobilized via amine group 1018 
on two flow cells of a CM5 sensor chip. For the immobilization, anti-human IgG Ab diluted in 10mM 1019 
Na acetate pH 5.0 at the concentration of 25 µg/mL was injected for 360 sec over the dextran 1020 
matrix, which had been previously activated with a mixture of 0.1M 1-ethyl-3(3-1021 
dimethylaminopropyl)-carbodiimide (EDC) and 0.4 M N-hydroxyl succinimide (NHS) for 420 sec. 1022 
After injection of the antibody, Ethanolamine 1M was injected to neutralize activated group. 10 1023 
µL/min flow rate was used during the whole procedure. Anti-SPIKE protein human mAbs were 1024 
diluted in HBS-EP+ (Hepes 10 mM, NaCl 150 mM, EDTA 3.4 mM, 0.05% p20, pH 7.4) and injected 1025 
for 120 sec at 10 µL/min flow rate over one of the two flow cells containing the immobilized Anti-1026 
Human IgG Antibody, while running buffer (HBS-EP+) was injected over the other flow cell to be 1027 
taken as blank. Dilution of each mAb was adjusted in order to have comparable levels of RU for 1028 
each capture mAb. Following the capture of each mAb by the immobilized anti-human IgG 1029 
antibody, different concentrations of SPIKE protein (20 µg/mL, 10 µg/mL, 5 µg/mL, 2.5 µg/mL and 1 1030 
µg/mL in HBS-EP+) were injected over both the blank flow cell and the flow cell containing the 1031 
captured mAb for 180 sec at a flow rate of 80 µL/min. Dissociation was followed for 800 sec, 1032 
regeneration was achieved with a pulse (60 sec) of Glycine pH 1.5. Kinetic rates and affinity 1033 
constant of SPIKE protein binding to each mAb were calculated applying a 1:1 binding as fitting 1034 










Autoreactivity screening test on HEp-2 Cells 1037 
The NOVA Lite HEp-2 ANA Kit (Inova Diagnostics) was used in accordance to the manufacturer’s 1038 
instructions to test antibodies the autoreactivity of selected antibodies which were tested at a 1039 
concentration of 100 µg/mL. Kit positive and negative controls were used at three different dilutions 1040 
(1:1, 1:10 and 1:100). Images were acquired using a DMI3000 B microscope (Leica) and an 1041 
exposure time of 300 ms, channel intensity of 2000 and a gamma of 2. 1042 
 1043 
Genetic Analyses of SARS-CoV-2 S-protein specific nAbs 1044 
A custom pipeline was developed for the analyses of antibody sequences and the characterization 1045 
of the immunoglobulin genes.  Raw sequences were stored as ab1 file and transformed into fastaq 1046 
using Biopython. The reads were then quality checked using FastQC 1047 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and a report was generated using 1048 
MultiQC (https://multiqc.info/). The antibody leader sequence and the terminal part of the constant 1049 
region were removed by trimming using Trimmomatic 1050 
(http://www.usadellab.org/cms/?page=trimmomatic). This latter program was also used to scan and 1051 
remove low-quality reads using a sliding-window parameter. Once sequences were recovered, 1052 
germline gene assignment and annotation were perfromed with MiXCR 1053 
(https://mixcr.readthedocs.io/en/master/index.html), using the single-read alignment parameters, 1054 
and a CSV-formatted output was generated. Finally, the sequences retrieved from the antibodies 1055 
described in this manuscript were compared to published neutralizing antibodies against SARS-1056 
CoV-2. For this purpose, the Coronavirus Antibody Database, CoV-AbDab 1057 
(http://opig.stats.ox.ac.uk/webapps/covabdab/) was downloaded and the antibodies with reported 1058 
neutralization activity against SARS-CoV-2 were extracted. Comparison analysis were performed 1059 
in Python using NumPy (https://numpy.org/) and, Pandas (https://pandas.pydata.org/) while figures 1060 













Negative-stain electron microscopy 1065 
Complexes were formed by incubating SARS-2 CoV-GSAS-6P-Mut7 and respective fabs at a 1:3 1066 
(trimer to fab) molar ratio for 30 minutes at room temperature. After diluting to 0.03 mg/ml in 1X 1067 
TBS pH 7.4, the samples were deposited on plasma-cleaned copper mesh grids and stained with 1068 
2% uranyl formate for 55 seconds. Automated data collection was made possible through the 1069 
Leginon software (Suloway et al., 2005) and a FEI Tecnai Spirit (120keV, 56,000x mag) paired with 1070 
a FEI Eagle (4k by 4k) CCD camera. Other details include a defocus value of -1.5 µm, a pixel size 1071 
of 2.06 Å per pixel, and a dose of 25 e−/Å2. Raw micrographs were stored in the Appion database 1072 
(Lander et al., 2009), particles were picked with DoGPicker (Voss et al., 2009), and 2D and 3D 1073 
classification and refinements were performed in RELION 3.0 (Scheres, 2012). Map segmentation 1074 
and model docking was done in UCSF Chimera (Pettersen et al., 2004).  1075 
 1076 
Prophylactic and therapeutic passive transfer studies in golden Syrian hamsters 1077 
Six- to eight-month-old female Syrian hamsters were purchased from Charles River Laboratories 1078 
and housed in microisolator units, allowed free access to food and water and cared for under U.S. 1079 
Department of Agriculture (USDA) guidelines for laboratory animals. For the passive transfer 1080 
prophylactic experiments, the day prior to SARS-CoV-2 infection six hamsters per group were 1081 
intraperitoneally administered with 500 µL of a 4, 1 or 0.25 mg/kg dose of J08-MUT mAb. For the 1082 
passive transfer therapeutic experiments, the day after SARS-CoV-2 infection six hamsters per 1083 
group were intraperitoneally administered with 500 µL of a 4 mg/kg dose of J08-MUT mAb. Another 1084 
two groups (n=6/each) were administered with 500 µL of 4 mg/kg of the anti-influenza virus #1664 1085 
human mAb (manuscript in preparation) or PBS only to serve as human IgG1 isotype and mock 1086 
control groups, respectively. The day after, hamsters were anesthetized using 5% isoflurane, and 1087 
inoculated with 5 x 105 PFU of SARS-CoV-2 (2019-nCoV/USA-WA1/2020) via the intranasal route, 1088 
in a final volume of 100 µL. Baseline body weights were measured before infection as well as 1089 
monitored daily for 7 and 11 days post infection in the prophylactic and therapeutic studies 1090 
respectively. All experiments with the hamsters were performed in accordance with the NRC Guide 1091 










Microbiological and Biomedical Laboratories as well as the guidelines set by the Institutional 1093 
Animal Care and Use Committee (IACUC) of the University of Georgia who also approved the 1094 
animal experimental protocol. All animal studies infection with SARS-CoV-2 were conducted in the 1095 
Animal Health Research Center (AHRC) Biosafety Level 3 (BSL-3) laboratories of the University of 1096 
Georgia. 1097 
 1098 
Determination of viral load by TCID50 assay 1099 
Lung tissues were homogenized in 1 mL of DMEM containing 1% fetal bovine serum (FBS) and 1% 1100 
penicillin/streptomycin. The lung homogenate supernatant was diluted 10-fold (100 to 106) and 1101 
used to determine median tissue culture infection dose (TCID50) in Vero E6 cells as previously 1102 
described (Jang and Ross, 2020). 1103 
 1104 
Human IgG detection in hamster sera 1105 
ELISA assay was used to detect the human IgG J08-MUT in hamster sera. 384-well plates (384 1106 
well plates, Microplate Clear; Greiner Bio-one) were coated with 2 µg/mL of unlabled goat anti-1107 
human IgG (SouthernBiotech) diluted in sterile PBS and incubated at 4°C overnight. 50 µL/well of 1108 
saturation buffer (PBS/BSA 1%) was used to saturate unspecific binding and plates were incubated 1109 
at 37°C for 1h without CO2. Hamster sera were diluted in PBS/BSA 1%/Tween20 0.05% at a 1110 
starting dilution of 1:10. Fourteen reciprocal dilutions were performed. Alkaline phosphatase-1111 
conjugated goat anti-human IgG (Sigma-Aldrich) was used as secondary antibody and pNPP (p-1112 
nitrophenyl phosphate) (Sigma-Aldrich) was used as soluble substrate. Wells were washed three 1113 
times between each step with PBS/BSA 1%/Tween20 0.05%. The final reaction was measured by 1114 
using the Varioskan Lux Reader (Thermo Fisher Scientific) at a wavelength of 405 nm. Samples 1115 
were considered as positive if OD at 405 nm (OD405) was twice the blank. 1116 
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Extremely potent neutralizing human monoclonal antibodies, though rare, are isolated from 
COVID-19 convalescent patients and suitable for prophylactic and therapeutic interventions of wild 
type SARS-CoV-2 as well as emerging variants.  
 
HIGHLIGHTS 
• Human memory B cells encoding extremely potent neutralizing antibodies are rare. 
• Most potent antibodies recognize the tip of the spike receptor binding domain. 
• Selected neutralizing antibody neutralizes SARS-CoV-2 emerging variants. 
• Potent antibody prevents and treats hamster infection without Fc-functions 
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